Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
2023-09-27 11:35:01 ET More on CRISPR Therapeutics CRISPR Therapeutics: CEO Targets $25bn Valuation - Exa-Cel Approval Is First Step Crispr Therapeutics: The Chance To Load Up Is Finally Here (Technical Analysis) CRISPR Therapeutics AG (CRSP) Presents at Citi's 18th ...
2023-09-27 10:25:40 ET More on Ionis Pharmaceuticals, Roche Roche: Positive Readouts From Pipeline Roche: 2023 Should Mark The Bottom Ionis Pharmaceuticals: Mid-Sized Pharma Is A Strong Buy Opportunity For All-Comers Ionis late-stage rare disease data fails t...
2023-09-27 08:59:28 ET Summary Poseida Therapeutics exhibits robust financials with Q2 2023 collaboration revenue surging to $20.01M and a recent $50M Astellas investment extending its cash runway. Despite stock underperformance, Poseida's diversified CAR-T pipeline shows momentum...
2023-09-23 16:00:00 ET More on GE Healthcare, Siemens, Biogen GE Healthcare: Revenue Growth, Margin Expansion And Attractive Valuation Siemens Healthineers: The Decline Makes The Upside Better Why Did GE HealthCare Excel Beyond The COVID-19 Crisis? Biogen: Le...
2023-09-21 18:10:58 ET Summary Mereo BioPharma's extended financial runway and reduced R&D spend improve its short-term risk profile. Diverse pipeline, led by setrusumab and alvelestat, offers long-term growth but awaiting key clinical readouts. The company's etigilimab co...
2023-09-20 15:26:50 ET More on COVID-19 test makers Compare metrics for ABT to BDX, RHHBF Roche: Positive Readouts From Pipeline Roche: 2023 Should Mark The Bottom Abbott Laboratories: Buy This Fairly Valued Dividend King For Consistently Rising Income ...
2023-09-20 13:00:27 ET More on Roche Roche: Positive Readouts From Pipeline Roche: 2023 Should Mark The Bottom Roche: FX Drug But Positive Outlook Roche granted U.K. approval for subcutaneous Tecentriq Roche sends anti-TIGIT developers higher after ca...
2023-09-20 12:30:54 ET Summary Roche has optionality to grow its pipeline with selective M&A and new partnerships. The company also confirmed better pharmaceutical growth expectations. We evaluated the three biggest readouts, Elevidys, TIGIT, and Inavolisib, providing supporti...
2023-09-20 08:30:53 ET NetworkNewsWire Editorial Coverage New York, NY – September 20, 2023 – More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation...
2023-09-19 14:45:33 ET Summary Regeneron Pharmaceuticals, Inc. is a pharmaceutical company headquartered in Tarrytown that has played a key role in the fight against COVID-19. Regeneron's revenue for the second quarter of 2023 was $3.16 billion, an increase of 10.5% compared to th...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Roche Holding Ltd ADR Website:
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
– Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR) – – Safety data were consistent with the known safety profile for Susvimo in people...